A large database from many comparative clinical trials in several indications is available for assessing the cardiac thrombosis risk associated with dabigatran, compared with well-controlled warfarin treatment. It points in the same direction: Recipients of dabigatran had more cardiac ischemic and thrombotic events. In the > 18,000-patient trial comparing two dosage regimens of dabigatran with warfarin to prevent embolic complications in atrial fibrillation, dabigatran was associated with 1.38 and 1.35 times the risk of myocardial infarction compared with warfarin for the 150 mg bid and 110 mg bid dabigatran regimens (P = .05 and .07, NNH = 476 and 526, respectively).4 The lower dosage is not approved in the United States. A correction5 published later by the authors declaring they undercounted heart attacks (by 32) and also embolic events (by four) and major bleeds (by 68 or 69) edged the increased heart attack risk just into statistical insignificance. In acute VTE treatment, where acute coronary syndrome while taking active anticoagulant therapy was uncommon, the pooled odds for two clinical trials6,7 of acute coronary syndrome for patients receiving dabigatran vs warfarin was 1.8 (95% CI, 0.6-6.2; NNH = 313) but nonsignificant, with only 747 patients receiving dabigatran and 692 receiving warfarin in the first, and 976 and 952, respectively, in the second, completing 6 months of anticoagulant therapy.